@article{eb7a4fb6275448eea7646bfa1eb41dec,
title = "Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials",
abstract = "Purpose: Dose information from organ sub-regions has been shown to be more predictive of genitourinary toxicity than whole organ dose volume histogram information. This study aimed to identify anatomically-localized regions where 3D dose is associated with genitourinary toxicities in healthy tissues throughout the pelvic anatomy. Methods and Materials: Dose distributions for up to 656 patients of the Trans-Tasman Radiation Oncology Group 03.04 RADAR trial were deformably registered onto a single exemplar CT dataset. Voxel- based multiple comparison permutation dose difference testing, Cox regression modeling and LASSO feature selection were used to identify regions where 3D dose-increase was associated with late grade ≥ 2 genitourinary dysuria, incontinence and frequency, and late grade ≥ 1 haematuria. This was externally validated by registering dose distributions from the RT01 (up to n = 388) and CHHiP (up to n = 247) trials onto the same exemplar and repeating the voxel-based tests on each of these data sets. All three datasets were then combined, and the tests repeated. Results: Voxel-based Cox regression and multiple comparison permutation dose difference testing revealed regions where increased dose was correlated with genitourinary toxicity. Increased dose in the vicinity of the membranous and spongy urethra was associated with dysuria for all datasets. Haematuria was similarly correlated with increased dose at the membranous and spongy urethra, for the RADAR, CHHiP, and combined datasets. Some evidence was found for the association between incontinence and increased dose at the internal and external urethral sphincter for RADAR and the internal sphincter alone for the combined dataset. Incontinence was also strongly correlated with dose from posterior oblique beams. Patients with fields extending inferiorly and posteriorly to the CTV, adjacent to the membranous and spongy urethra, were found to experience increased frequency. Conclusions: Anatomically-localized dose-toxicity relationships were determined for late genitourinary symptoms in the urethra and urinary sphincters. Low-intermediate doses to the extraprostatic urethra were associated with risk of late dysuria and haematuria, while dose to the urinary sphincters was associated with incontinence.",
keywords = "dose-toxicity relationships, external beam radiotherapy, prostate cancer, urinary toxicity, voxel-based analysis",
author = "Marco Marcello and Denham, {James W.} and Angel Kennedy and Annette Haworth and Allison Steigler and Greer, {Peter B.} and Holloway, {Lois C.} and Dowling, {Jason A.} and Jameson, {Michael G.} and Dale Roach and Joseph, {David J.} and Gulliford, {Sarah L.} and Dearnaley, {David P.} and Sydes, {Matthew R.} and Emma Hall and Ebert, {Martin A.}",
note = "Funding Information: We acknowledge all trial investigators and patients who've made this study possible. We gratefully acknowledge the support of the Sir Charles Gairdner Hospital, Rachel Kearvell, the Elvis study team including Kristie Harrison, participating RADAR centers, the Trans-Tasman Radiation Oncology Group, Ben Hooton and Elizabeth van der Wath. We are also grateful for the contributions of Oscar Acosta, Renaud de Crevoisier, and Eugenia Mylona. Funding. We acknowledge funding from the Australian National Health and Medical Research Council (Grants nos. 300705, 455521, 1006447, and 1077788), the Hunter Medical Research Institute, the Health Research Council (New Zealand), the University of Newcastle, the Calvary Mater Newcastle, the Medical Research Council Clinical Trials Unit at University College London, Abbott Laboratories and Novartis Pharmaceuticals. These funders (Abbott Laboratories and Novartis Pharmaceuticals) were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. We acknowledge funding from the Medical Research Council UK (grant MC_UU_12023/28) for the MRC RT01 trial. DD, EH, and SG acknowledge NHS funding to the National Institute for Health Research (NIHR) Biomedical Research Center at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. We acknowledge support of Cancer Research UK (C8262/A7253, C1491/A9895, C1491/A15955, SP2312/021), the Department of Health, the NIHR Cancer Research Network for the CHHiP trial. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Marcello, Denham, Kennedy, Haworth, Steigler, Greer, Holloway, Dowling, Jameson, Roach, Joseph, Gulliford, Dearnaley, Sydes, Hall and Ebert.",
year = "2020",
month = jul,
day = "22",
doi = "10.3389/fonc.2020.01174",
language = "English",
volume = "10",
pages = "1--20",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S.A.",
}